Prostate Cancer - Results from #740

REVIEW UroToday

Looking back at the preclinical discovery of enzalutamide, "Beyond the Abstract," by Yun-Sok Ha, MD, PhD and Isaac Yi Kim, MD, PhD August 19, 2014

Global transcriptome analysis of formalin-fixed prostate cancer specimens identifies biomarkers of disease recurrence, "Beyond the Abstract," by Carlos S. Moreno, PhD August 14, 2014

A systematic literature review of well-designed studies comparing image-guided targeted biopsies versus systematic randomized biopsies in the detection of prostate cancer, "Beyond the Abstract," by Jochen Walz August 12, 2014

Health care costs for treatment and for adverse events in prostate cancer patients receiving androgen deprivation therapy, "Beyond the Abstract," by Karen E. Bremner, BSc August 12, 2014

Transurethral resection of the prostate significantly affects acute and long-term urinary quality of life after radiotherapy for prostate cancer, "Beyond the Abstract," by Michael Pinkawa, MD August 11, 2014

United States Preventative Services Task Force (USPSTF) recommendations sway patient perceptions of prostate cancer screening, "Beyond the Abstract," by Matthew J. Maurice, MD August 8, 2014

Application of the spacer to mitigate rectum toxicity in prostate cancer radiation therapy, "Beyond the Abstract," by Michael Pinkawa, MD August 7, 2014

A new paradigm for prostate cancer treatment: Extracellular vesicle therapy, "Beyond the Abstract," by Devasis Chatterjee, Joseph F. Renzulli II, and Peter J. Quesenberry August 5, 2014

Free PSA in men with clinical BPH has limited value, "Beyond the Abstract," by Anil Mandhani August 1, 2014

Why use Partin tables, nomograms, or predictive models in my patients, and how can I counsel them with their individual probability? "Beyond the Abstract," by Ángel Borque, MD, PhD July 30, 2014

Provider practice patterns and antimicrobial stewardship, "Beyond the Abstract," by Matthew Mossanen, MD and John L. Gore, MD, MS, FACS July 25, 2014

Radio-immunotherapy adjuvant to androgen deprivation therapy for prostate cancer, "Beyond the Abstract," by Raymond A. Clarke and Barry Allen July 14, 2014

4D ultrasound speckle tracking of intra-fraction prostate motion, "Beyond the Abstract," by Tuathan O'Shea July 11, 2014

Clinical performance of serum isoform [-2]proPSA (p2PSA) and its derivatives, namely %p2PSA and PHI (Prostate Health Index) in men younger than 60 years of age, "Beyond the Abstract," by Nicola Fossati, et al July 11, 2014

Prostate cancer genetic-susceptibility locus on chromosome 20q13 is androgen receptor-regulated and amplified in metastatic tumors, "Beyond the Abstract," by David P. Labbé, PhD July 1, 2014

"Beyond the Abstract" - A double-blind, placebo-controlled randomised trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer-the UK NCRN Pomi-T study, by Robert Thomas, et al July 1, 2014

Modified ultradissection reduces pT2 positive surgical margins on the bladder neck in robot-assisted radical prostatectomy, "Beyond the Abstract," by Motoo Araki, MD, PhD June 27, 2014

Results of a prospective phase IIa feasibility study of primary zonal high-intensity focused ultrasound for prostate cancer, "Beyond the Abstract," by Aoun Fouad, MD June 25, 2014

Neoadjuvant therapy for localized prostate cancer, "Beyond the Abstract," by David Y. Lou, MD, PhD and Lawrence Fong, MD June 24, 2014

Increased DHT levels in androgenic alopecia have been selected for to protect men from prostate cancer, "Beyond the Abstract," by Shiva Bhargava June 19, 2014

Page 38 of 57